Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
Company to host webcast tomorrow at 8:00 a.m. EDT NEW YORK — Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast tomorrow at 8 a.m. EDT to […]
Definium Therapeutics will host a live webcast on September 14, 2026, at 8 a.m. EDT to discuss topline results from its Panorama Phase 3 study. The study evaluated DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD).
The Panorama study, according to Investing.com, was a multicenter, randomized, double-blind, placebo-controlled trial that enrolled 245 participants aged 18 to 74 years across approximately 32 study centers. Participants were randomized 2:1:2 to receive a single dose of DT120 ODT 100 µg, DT120 ODT 50 µg, or matching placebo.
The study consisted of a 12-week double-blind treatment period followed by a 40-week open-label extension. The primary endpoint was change from baseline in Hamilton Anxiety Rating Scale total score at Week 12.
Brief written by urgent.news from Financial Post, Investing.com — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
